CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

Stock Information for Cel-Sci Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cel-Sci Corporation

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025
CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference
CEL-SCI Announces Closing of $10 Million Public Offering
CEL-SCI Announces Pricing of $10 Million Public Offering
CEL-SCI Announces Proposed Public Offering
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.